[{"address1": "2223 Avenida de la Playa", "address2": "Suite 208", "city": "LA Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "619 400 1170", "website": "https://www.gribio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Dr. W. Marc Hertz Ph.D.", "age": 53, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vipin  Kumar Chaturvedi Ph.D.", "age": 64, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1959, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leanne M. Kelly", "age": 46, "title": "CFO & Corporate Secretary", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Albert  Agro Ph.d.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 2.87, "open": 2.71, "dayLow": 1.7, "dayHigh": 2.71, "regularMarketPreviousClose": 2.87, "regularMarketOpen": 2.71, "regularMarketDayLow": 1.7, "regularMarketDayHigh": 2.71, "volume": 279127, "regularMarketVolume": 279127, "averageVolume": 96884, "averageVolume10days": 224388, "averageDailyVolume10Day": 224388, "bid": 1.72, "ask": 1.79, "bidSize": 1400, "askSize": 3100, "marketCap": 1130057, "fiftyTwoWeekLow": 1.7, "fiftyTwoWeekHigh": 93.31, "fiftyDayAverage": 2.9763877, "twoHundredDayAverage": 18.675093, "currency": "USD", "enterpriseValue": -2128994, "floatShares": 367042, "sharesOutstanding": 645747, "sharesShort": 22202, "sharesShortPriorMonth": 23920, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.0344, "heldPercentInsiders": 0.20692, "heldPercentInstitutions": 0.065560006, "shortRatio": 1.02, "shortPercentOfFloat": 0.040999997, "impliedSharesOutstanding": 645747, "bookValue": 5.273, "priceToBook": 0.3318794, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -13302000, "trailingEps": -31.5, "lastSplitFactor": "1:7", "lastSplitDate": 1706572800, "enterpriseToEbitda": 0.198, "52WeekChange": -0.95224226, "SandP52WeekChange": 0.19561028, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GRI", "underlyingSymbol": "GRI", "shortName": "GRI Bio, Inc.", "longName": "GRI Bio, Inc.", "firstTradeDateEpochUtc": 1682343000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "2a4b9e2e-4254-393c-ba83-44e16bef237a", "messageBoardId": "finmb_136941170", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.75, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 3488000, "totalCashPerShare": 7.521, "ebitda": -10774000, "totalDebt": 28000, "quickRatio": 1.602, "currentRatio": 2.006, "debtToEquity": 1.257, "returnOnAssets": -2.92499, "freeCashflow": -6234000, "operatingCashflow": -4274000, "financialCurrency": "USD", "trailingPegRatio": null}]